Genesis Research and Development, which in July abandoned plans to merge with an unlisted Australian company, is seeking legal advice and will make an announcement on its future amid a lack of funds to continue operating.
The company had its shares halted from trading on the NZX and ASX pending a statement.
In its notice to the ASX, it says the trading halt will end "when legal advice is received and an announcement is made about the future of the company due to the lack of funds for ongoing costs".
The company suspended operations in May 2010 and laid off its entire staff.
In July this year it placed 9.1 million shares, which it said gave it enough funds to remain listed while it considers further investments.
The shares last traded at 1.8 cents, valuing the company at $980,000, and have declined 40% in the past year.
In July, Genesis called off a proposed merger with Australia-based Mariposa Health, an unlisted public pharmaceutical development company.
This article is tagged with the following keywords. Find out more about MyNBR Tags
- Commerce Commission reveals the most complained-about companies
- Trump's debate meltdown: will it cost him?
- MARKET CLOSE: NZ shares drop, Orion Health and Xero lead index lower while Air NZ bounces
- Where the polls stand on the eve of the first US presidential debate
- Spark says 130,000 Xtra mail address at risk after Yahoo hack
Most listened to
- No knockout blows in first presidential debate, says NBR's Nevil Gibson
- Intueri's problems raise questions for the board, says Martin Watson of the Shareholders Association
- ANZ's Philip Borkin and NBR's Jason Walls on what's next for the kiwi dollar on Currency Talk
- AngelEquity's Bill Murphy on why his platform won't cater for retail investors
- Spark exec Jason Paris defends his company's honour after it tops ComCom's most-complained-about list
- FMA lawyer Justin Smith counters the Goldman Sachs defence